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 2 
ABSTRACT 1 
Background and Purpose. Whilst cancer is a risk factor for acute ischaemic stroke (AIS), its 2 
impact on AIS prognosis between metastatic and non-metastatic (MC and NMC) disease is 3 
poorly understood. Furthermore, the receipt of intravenous thrombolysis (IVT) and 4 
endovascular thrombectomy (ET) and their outcomes is poorly researched. 5 
Methods. AIS admissions from the National Inpatient Sample (NIS) were included (October 6 
2015-December 2017). Multivariable logistic regressions adjusting for a wide range of 7 
confounders analysed the relationship between NMC and MC and AIS in-hospital outcomes 8 
(mortality, prolonged hospitalisation >4 days and routine home discharge). Interaction terms 9 
with IVT and ET were also computed to explore their impact amongst cancer patients.  10 
Results. 221,249 records representative of 1,106,045 admissions were included. There were 11 
38,855 (3.51%) patients with co-morbid cancers: NMC=53.78% and MC=46.22%. NMC was 12 
associated with 23% increased odds of in-hospital mortality (odds ratio (95% confidence 13 
interval) = 1.23 (1.07-1.42)), which was mainly driven by pancreatic and respiratory cancers. 14 
This association was entirely offset by both IVT and ET. MC was associated with 2-fold 15 
increased odds of in-hospital mortality (2.16 (1.90-2.45)), which was mainly driven by 16 
respiratory, pancreatic and colorectal cancers. This association was only offset by ET. Both 17 
NMC and MC were significantly associated with prolonged hospitalisation and decreased 18 
odds of routine discharge.    19 
Conclusions. Cancer patients are at higher odds of acute adverse outcomes after AIS and 20 
warrant robust primary prevention. IVT and ET improve these outcomes and should thus be 21 
offered routinely unless otherwise contraindicated in this group of stroke patients. 22 
Keywords: ischaemic stroke; cancer; mortality; revascularisation; thrombolysis; 23 
thrombectomy; 24 
  25 
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 3 
NON-STANDARD ABBREVIATIONS AND ACRONYMS 1 
AIS - Acute Ischaemic Stroke; ET - Endovascular Thrombectomy; HCUP - Healthcare Cost 2 
and Utilisation Project; ICD-19 - International Classification of Disease – tenth edition; IVT - 3 
Intravenous Thrombolysis; LoS - Length of stay; MC - Metastatic Cancer; NIS - National 4 
Inpatient Sample; NMC - Non-metastatic Cancer; US - United States;   5 
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INTRODUCTION 1 
 Malignancy is associated with increased risk of acute ischaemic stroke (AIS)1. This is 2 
mediated through a variety of mechanisms, including hypercoagulability2 and shared risk 3 
factors1. Cancer is therefore important to consider in AIS, as it may not only be more 4 
prevalent amongst AIS patients3, but also be associated with adverse outcomes4,5. Despite 5 
that fact that cancer is a heterogenous disease, the distribution of organ-specific primary 6 
cancer types amongst AIS patients and the magnitude of the association between each cancer 7 
type and adverse AIS outcomes remain largely unknown. 8 
Revascularisation therapies (intravenous thrombolysis – IVT and endovascular 9 
thrombectomy - ET) significantly improve AIS outcomes6,7 and are thus recommended 10 
routinely in eligible patients8. Nevertheless, co-morbid cancer may hinder their use given that 11 
this population is more likely to exhibit contraindications to IVT or ET1. Current guidelines 12 
recommend IVT in AIS patients with systemic malignancy provided they have a life 13 
expectancy >6 months and no contraindications8. These recommendations are based on 14 
limited evidence, as landmark randomised controlled trials studying IVT9–12 or ET7 have 15 
excluded cancer patients. Previous smaller scale observational studies of AIS patients with 16 
cancer have found no increased haemorrhagic complications or mortality associated with 17 
IVT13–15. Nevertheless, guidelines currently provide no specific recommendations regarding 18 
ET for this population8, with the efficacy and safety of ET amongst AIS patients with cancer 19 
being largely unclear. While several small retrospective studies have found no association 20 
between cancer and adverse outcomes in AIS patients undergoing ET16,17, others have 21 
identified significantly higher mortality in cancer patients18.  22 
This drives the need for a comprehensive description of the association between 23 
cancer and AIS outcomes in contemporary clinical practice and whether revascularisation 24 
therapies have an effect on these outcomes. In this study of a representative sample of AIS 25 
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 5 
admissions in the United States (US) between 2015-2017, we sought examine the prevalence 1 
of comorbid cancer among patients with AIS and its association with in-hospital outcomes, 2 
also stratifying by metastatic disease. We also aimed to examine the effect of IVT/ET on 3 
outcomes in cancer patients through the use of interaction terms.   4 
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METHODS 1 
This study was conducted in accordance with the principles of the Declaration of 2 
Helsinki (1975) and later amendments. The data that support the findings of this study are 3 
available from the corresponding author upon reasonable request. 4 
Data source and inclusion criteria 5 
 The National Inpatient Sample (NIS) is a publicly available database containing >7 6 
million annual hospital admission records. NIS contains admission records representing a 20% 7 
stratified sample of all community hospital admissions in the United States. Using the 8 
provided sampling weights, the NIS data can be used to provide national estimates for the 9 
sampling population, representative of ~95% of the US population19,20. Prior to undertaking 10 
this project, all authors completed the Healthcare Cost and Utilisation Project (HCUP) Data 11 
Use Agreement Training Tool. All authors also read and signed the Data Use Agreement for 12 
Nationwide Databases. As the NIS is publicly available and contains no patient identifiable 13 
information, no ethical approval was needed. Using data files containing annual admissions 14 
between 2015-2017, all records with a primary diagnosis of ischaemic stroke (International 15 
Classification of Disease – tenth edition (ICD-10) codes I63.0-I63.9) were extracted. Only 16 
cases admitted between October 2015-December 2017 were included due to a change in co-17 
morbidity coding (ICD-9 to ICD-10) occurring after September 201520. Elective admissions 18 
and those with missing data on key variables were excluded.  19 
Statistical Analysis 20 
 All analyses were performed using Stata 15.1SE, Stata Statistical Software. A 5% 21 
threshold of statistical significance was utilised for all analyses (P < 0.05). Analyses were 22 
performed following HCUP guidelines21, utilising the provided discharge weights as 23 
probability weights and survey data analysis techniques stratifying by NIS stratum and year 24 
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of admission22 in order to account for patient clustering within hospitals and produce US-1 
wide estimates23. 2 
Outcomes 3 
The following outcomes were analysed: (1) in-hospital mortality, (2) prolonged 4 
hospital stay in excess of 4 days and (3) routine discharge from hospital. Vital status upon 5 
hospital discharge (dead/alive) and the length of stay (LoS) in hospital are provided as 6 
standard variables in the NIS24,25. Prolonged hospitalisation was defined as LoS >4 days, 7 
according to expert clinical opinion and previous studies assessing ischaemic stroke 8 
outcomes amongst patients admitted to hospital in the United States26. A dichotomous 9 
variable indicating patients hospitalised for >4 days was subsequently used as an outcome for 10 
LoS analyses.  Discharge status was coded using the provided discharge destination27. All 11 
records of patients who were discharged against medical advice and those discharged to an 12 
unknown destination were excluded from the analyses prior to weighting (n=2187 (0.99 %)), 13 
allowing estimates for this particular outcome to be provided for 1,095,110 (99.01%) of AIS 14 
patients. Discharge destination was then dichotomised into routine discharges and other 15 
discharges (‘home health care’, ‘short-term hospital’, ‘other facilities including intermediate 16 
care and skilled nursing home’ and ‘died in hospital’). The ‘other discharges’ category was 17 
subsequently used as a reference category in all analyses evaluating discharge destination. 18 
Exposures and confounders 19 
 Co-morbid cancer (non-metastatic and metastatic) as well as the organ-specific types 20 
were the exposures of interest. All models were adjusted for the following confounders: age, 21 
sex, ethnicity, Elixhauser co-morbidities (congestive heart failure, valvular disease, 22 
pulmonary circulatory disease, peripheral vascular disease, paralysis, other neurological 23 
disorders, chronic pulmonary disease, diabetes, hypothyroidism, renal failure, liver disease, 24 
peptic ulcer disease, acquired immune deficiency syndrome, rheumatoid arthritis, 25 
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 8 
coagulopathy, obesity, weight loss, fluid and electrolyte disorders, anaemia, alcohol abuse, 1 
drug abuse, psychosis, depression and hypertension), previous history of cancer, 2 
haematological malignancies, other co-morbidities (dyslipidaemia, smoking, Parkinson 3 
disease, coronary heart disease, all-cause bleeding, pulmonary embolism, deep venous 4 
thrombosis, atrial fibrillation, arrhythmias other than atrial fibrillation, pneumonia (incl. 5 
aspiration), shock, previous cerebrovascular disease), hospital bedsize, location & teaching 6 
status and revascularisation therapy (thrombolysis, thrombectomy). Adjusting co-variates 7 
were selected based on clinical judgement and previous literature5,14,15,28. 8 
Co-morbid non-metastatic and metastatic cancer diagnoses were identified using the 9 
Elixhauser co-morbidities29: solid tumour without metastases and metastatic cancer, 10 
respectively. Specific cancer types were identified using the Clinical Classification Software 11 
Refined (CCSR) codes (Supplemental Table I - please see 12 
https://www.ahajournals.org/journal/str)30. Previous history of cancer was identified using 13 
ICD10 codes Z85.x and Z86.0x. Elixhauser co-morbidities were determined using the HCUP 14 
Elixhauser co-morbidity software version 2020.129. Co-morbid conditions other than the 15 
Elixhauser co-morbidities were identified using ICD-10 codes (Supplemental Table II - 16 
please see https://www.ahajournals.org/journal/str). 17 
 18 
 19 
Descriptive Statistics 20 
 Patient characteristics were compared between AIS patients without cancer, those 21 
with non-metastatic cancer and those with metastatic disease. One-way analysis of variance 22 
and Pearson’s χ2 test were employed to compare patient characteristics for continuous and 23 
categorical variables, respectively. The distribution of each primary cancer type amongst the 24 
included sample as well as the proportion of metastatic disease amongst each cancer type 25 
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were determined. Patient characteristics were then also compared between AIS patients with 1 
the 5 most common types of primary cancers previously identified. No between-group tests 2 
of statistical significance were performed for these comparisons as the groups were not 3 
mutually exclusive. 4 
 5 
Association between prevalent cancer and odds of receiving revascularisation therapy 6 
 Multivariable logistic regressions were employed to analyse the relationship between 7 
co-morbid non-metastatic and metastatic cancer and the odds of receiving IVT and ET in 8 
hospital. All models were adjusted for the covariates listed above, with the exception of IVT 9 
or ET when this variable was used as the outcome. 10 
 11 
Association between non-metastatic and metastatic cancer and in-hospital outcomes 12 
 Multivariable logistic regressions were employed to analyse the relationship between 13 
co-morbid non-metastatic and metastatic cancer and in-hospital outcomes. Separate models 14 
containing interaction terms with IVT and ET were also computed to determine whether 15 
these relationships were modified by revascularisation therapies. All models were adjusted 16 
for the covariates listed above. 17 
 18 
Association between the five most common primary cancer types and in-hospital outcomes 19 
 Multivariable logistic regressions were employed to analyse the relationship between 20 
the five most common primary cancer types and in-hospital outcomes, stratifying each cancer 21 
type by the presence of metastases were also computed. All five cancer types were 22 
simultaneously introduced in the same model. All models were adjusted for the covariates 23 
listed above as well as other co-morbid cancer types. 24 
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RESULTS 1 
Figure 1 details the study population. Out of 230,177 records extracted with a primary 2 
diagnosis of ischaemic stroke between October 2015-December 2017, a total of 8708 elective 3 
admission records as well as 220 records with missing data were excluded, yielding a total of 4 
221,249 included records. After the application of sampling weights and the exclusion of 5 
strata with single sampling units, the included records were used to provide estimates for the 6 
population from which they were sampled: 1,106,045 patients admitted with a primary 7 
diagnosis of AIS. 8 
 9 
Descriptive Statistics 10 
 Figure 2 details the distribution of primary cancer types amongst the 38,855 AIS 11 
patients with co-morbid cancer, representing 3.51% of the entire included sample. The five 12 
most common types were: respiratory (9490 (24.42%)), prostate (4960 (12.77%)), breast 13 
(3375 (8.69%)), pancreatic (2640 (6.79%)) and colorectal cancers (2490 (6.41%)). There 14 
were 4750 (50.05%) metastatic respiratory cancer patients, 1250 (25.20%) metastatic prostate 15 
cancer patients, 1110 (32.89%) metastatic breast cancer patients, 1875 (71.02%) metastatic 16 
pancreatic cancer patients and 985 (39.56%) metastatic colorectal cancer patients. 17 
 Table 1 and Supplemental Table III (please see 18 
https://www.ahajournals.org/journal/str) detail the characteristics of the included patient 19 
population, representative of 1,106,045 AIS patients. The median (interquartile range) age 20 
was 72 (61-82) years and 50.41% were female. The median (interquartile range) length of 21 
stay was 3 (2-6) days. There were 20,895 (1.89%) patients with non-metastatic cancer and 22 
17,960 (1.62%) with metastatic cancer. Median age ranged between 70 and 75 years, highest 23 
among those with non-metastatic cancer and lowest amongst those with metastatic cancer. 24 
The highest proportion of females was recorded amongst patients with metastatic cancer 25 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted March 11, 2021. ; https://doi.org/10.1101/2021.03.09.21253211doi: medRxiv preprint 
 11
(51.03%), followed by those without active cancer (50.47%) and those with non-metastatic 1 
cancer (46.88%). Compared to patients without cancer, those with cancer had higher rates of 2 
prevalent chronic pulmonary disease, liver disease, coagulopathy and anaemia, but lower 3 
rates of congestive heart disease and diabetes. Compared to patients without cancer, those 4 
with cancer had higher rates of in-hospital mortality, prolonged hospitalisation and lower 5 
rates of routine discharge. 6 
 Supplemental Table IV (please see https://www.ahajournals.org/journal/str) details 7 
the characteristics of the included patients with the five most common co-morbid cancer 8 
types. Patients with prostate cancer were oldest, median (interquartile range) – 79 (71-85) 9 
years, followed by those with breast cancer – 74 (67-83) years, colorectal cancer – 74 (65-82) 10 
years, respiratory cancers – 71 (63-79) years and pancreatic cancer 71 (63-77) years. Patients 11 
with pancreatic cancer had the highest rate of in-hospital mortality (10.61%), followed by 12 
respiratory cancers (10.17%), colorectal cancer (6.22%), breast cancer (5.63%) and prostate 13 
cancer (3.73%).  14 
 15 
Association between prevalent cancer and odds of receiving revascularisation therapy 16 
Supplemental Table V (please see https://www.ahajournals.org/journal/str) details the 17 
results of the multivariable logistic regressions evaluating the associations between non-18 
metastatic and metastatic cancer and the odds of receiving thrombolysis or thrombectomy. 19 
Compared to patients without cancer, those with non-metastatic cancer had lower odds of 20 
receiving both IVT (odds ratio (95% confidence interval) – 0.77 (0.66-0.90)) and ET (0.80 21 
(0.63-0.9994)). Compared to patients without cancer, those with metastatic cancer had lower 22 
odds of receiving IVT (0.39 (0.32-0.47)) but not ET (0.87 (0.69-1.09)). 23 
 24 
Association between non-metastatic and metastatic cancer and in-hospital outcomes 25 
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 Figure 3 details the results of the multivariable logistic regressions assessing the 1 
associations between non-metastatic and metastatic cancer and in-hospital outcomes. Non-2 
metastatic cancer was associated with a 23% increase in the odds of in-hospital mortality 3 
(odds ratio (95% confidence interval) – 1.23 (1.07-1.42)). This association exhibited 4 
significant interactions with IVT and ET: non-metastatic cancer was not associated with 5 
increased in-hospital mortality amongst AIS patients undergoing either IVT or ET. Metastatic 6 
cancer was associated with a 2-fold increase in the odds of in-hospital mortality: 2.16 (1.90-7 
2.45). This association also exhibited a significant interaction with ET, but not IVT: 8 
metastatic cancer was not associated with increased in-hospital mortality amongst AIS 9 
patients undergoing ET. Non-metastatic and metastatic cancers were also associated with 10 
increased odds of prolonged hospitalisation and decreased odds of routine discharge.  11 
 12 
Association between the five most common primary cancer types and in-hospital outcomes 13 
 Figure 4 details the results of the multivariable logistic regression assessing the 14 
association between the five most common primary cancer types and in-hospital outcomes, 15 
stratifying by metastatic disease status. Respiratory cancers (both non-metastatic – 1.88 16 
(1.48-2.40) and metastatic – 2.40 (1.90-3.02)), pancreatic cancers (both non-metastatic (1.96 17 
(1.04-3.71)) and metastatic – 2.33 (1.61-3.37)) and metastatic colorectal cancer (2.08 (1.21-18 
3.58)) were associated with significantly increased in-hospital mortality. There were no 19 
associations between metastatic prostate cancer, breast cancer (both non-metastatic and 20 
metastatic) and non-metastatic colorectal cancer and in-hospital mortality.  Non-metastatic 21 
prostate cancer was associated with decreased odds of in-hospital mortality (0.62 (0.40-0.96)). 22 
Respiratory cancers, metastatic pancreatic and metastatic colorectal cancer were associated 23 
with increased odds of prolonged hospitalisation. Respiratory cancers, metastatic prostate 24 
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cancer, pancreatic cancer (both non-metastatic and metastatic) and metastatic colorectal 1 




In this study including a sample representative of 1,106,045 acute ischemic stroke 6 
patients admitted between 2015-2017, we have determined the distribution of prevalent 7 
cancers as well as their association with in-hospital outcomes. We have also determined how 8 
these associations are influenced by the use of revascularisation therapies.  9 
The five most common cancer types were: respiratory (24.42%), prostate (12.77%), 10 
breast (8.69%), pancreatic (6.79%) and colorectal cancers (6.41%). We report significant 11 
differences in stroke treatment according to cancer diagnosis, with patients with non-12 
metastatic cancer at 23% lower odds of receiving IVT and 20% lower odds of receiving ET. 13 
The disparities in treatments were even greater in patients with metastatic cancer who were at 14 
61% lower odds of receiving IVT compared to patients without cancer. Patients with cancer 15 
were at increased risk of adverse AIS outcomes. Non-metastatic cancer was associated with 16 
23% increased odds of in-hospital mortality, which was mainly driven by pancreatic (96% 17 
increased odds) and respiratory (88% increased odds) cancers. This association was entirely 18 
offset by both IVT and ET. Metastatic cancer was associated with 2-fold increased odds of 19 
in-hospital mortality, which was mainly driven by respiratory (2.43-fold increase), pancreatic 20 
(2.37-fold increase) and colorectal (2.11-fold) cancers. This association was only offset by 21 
ET. Non-metastatic and metastatic cancers were also associated with increased odds of 22 
prolonged hospitalisation and decreased odds of routine discharge. 23 
The association between co-morbid cancer and AIS outcomes has been previously 24 
evaluated on smaller, single-centre cohorts4,31,32. A previous investigation including ~5000 25 
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AIS patients out of whom 1.46% had co-morbid cancer found a 3.7-fold increase in the odds 1 
of in-hospital mortality4. Another study including 468 AIS patients with co-morbid cancer 2 
found that metastatic disease was independently associated with a 4.5-fold increase in the risk 3 
of 6-month mortality compared to non-metastatic cancers32. Furthermore, gastric and 4 
pancreatic cancers were associated with increased mortality risk compared to other cancer 5 
types32. Our results complement these previous findings by providing a comprehensive 6 
description of the association between these disease entities based on a large, national real-7 
world sample of AIS patients and highlight disparities in provision of evidence-based 8 
therapies.  9 
Furthermore, our results provide additional insight into these relationships by 10 
exploring differences based on the presence of metastases and between different primary 11 
types. We found 23% increased odds of in-hospital mortality associated with non-metastatic 12 
cancer, which may be attributed to a higher proportion of cryptogenic strokes4 with worse 13 
prognosis33  and increased hypercoagulability leading to complications such as venous 14 
thromboembolism, recurrent stroke 34 and a greater risk of haemorrhagic transformation. 15 
Another important contributor to the increased risk of adverse outcomes was significant 16 
differences in the receipt of IVT and ET, with patients with cancer consistently less likely to 17 
receive revascularisation therapies. 18 
Previous large clinical trials assessing the use of IVT for AIS revascularisation 19 
provide no specific information regarding AIS patients with cancer9–12. Nevertheless, several 20 
observational studies including AIS patients with co-morbid cancer have found no 21 
association between IVT and in-hospital mortality, major bleeding or functional 22 
outcomes13,14,35–38, while current guidelines recommend IVT in patients with systemic 23 
malignancy provided they have a life expectancy >6 months and no other contraindications8. 24 
We found that even after comprehensive adjustment, patients with co-morbid cancer were 25 
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less likely to receive IVT, suggesting that the lower rates of IVT in this population may not 1 
be fully explained by a higher prevalence of contraindications. This may reflect the fact that 2 
treating clinicians may be hesitant to use IVT solely based on cancer status, even in those 3 
with non-metastatic disease.  4 
Our work shows for the first time that IVT offset the increased in-hospital mortality 5 
and decreased odds of routine discharge associated with non-metastatic cancer, providing 6 
supportive evidence for IVT therapy in these patients. Nevertheless, the associations between 7 
metastatic cancer and adverse in-hospital outcomes were not offset by IVT, suggesting that 8 
AIS patients with metastatic cancer may not fully benefit from this therapy. This may relate 9 
to the fact that strokes in this patient group may also relate to the presence of cerebral 10 
metastases and not due to an in-situ thrombosis in the cerebral vessels, or that there was a 11 
greater likelihood of haemorrhagic transformation that offset any benefit with thrombolysis.  12 
As with IVT, clinical trials assessing the use of ET in AIS provide no specific data 13 
regarding its use in cancer patients7. Nevertheless, a few small retrospective observational 14 
studies have assessed the use of ET in Asian AIS patients with cancer, reaching different 15 
conclusions16,17,32. While similar acute outcomes were found amongst AIS patients with and 16 
without co-morbid cancer undergoing ET in two studies16,17, a third study found significantly 17 
worse functional outcomes in cancer patients treated with ET18. Furthermore, it has been 18 
postulated that AIS patients with cancer may have different clot composition, which may 19 
hinder successful recanalisation in this population16.  20 
Our analysis shows that patients with non-metastatic cancer were significantly less 21 
likely to receive ET, while those with metastatic disease were equally likely to receive ET 22 
compared to patients without cancer. These differences may reflect the fact that metastatic 23 
cancer patients may be more likely to present with cardioembolic strokes caused large artery 24 
occlusion, rendering them more likely candidates for ET. Nevertheless, in the absence of 25 
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more granular stroke syndrome data, we could not assess this hypothesis and further research 1 
is thus warranted. Our study provides for the first time an analysis of the relationship between 2 
cancer and ET in AIS patients using a large, real-world and contemporary sample. ET offset 3 
the excess odds of in-hospital adverse outcomes associated both with non-metastatic and 4 
metastatic cancers, suggesting that ET may be a successful strategy in eligible patients with 5 
cancer, especially in those with metastases who may not fully benefit from IVT.  6 
  Our study has several strengths, such as including a large sample representative 7 
of >1 million AIS patients admitted between late 2015-2017 across the United States as well 8 
as having adjusted for a wide range of important confounders. Our results thus reflect 9 
contemporary stroke management, including the more widespread adoption of ET and thus 10 
allow the generalisation of clinical implications to patients with similar characteristics. Our 11 
findings show that both non-metastatic and metastatic disease are associated with significant 12 
increases in in-hospital mortality, prolonged hospitalisation and decreased odds of routine 13 
home discharge. This highlights that cancer patients warrant thorough primary prevention, 14 
since they are not only more likely to suffer an incident stroke, but also at higher odds of 15 
acute adverse stroke outcomes. Given our large sample size, our study is able to provide more 16 
granular information regarding individual associations between each primary cancer type and 17 
adverse acute outcomes.  18 
Our study highlights inequalities in the receipt of evidence-based reperfusion 19 
therapies in cancer patients Such differences have also been described in other cardiovascular 20 
conditions such as myocardial infarction28. We report that cancer patients offered treatment 21 
with IVT or ET may derive a benefit and that IVT may offset the non-metastatic cancer-22 
associated excess odds of adverse outcomes. Furthermore, ET offsets the excess odds 23 
associated with both non-metastatic and metastatic disease. Along with previous findings, our 24 
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study also suggests that co-morbid cancer should not represent a contraindication to AIS 1 
revascularisation therapies in itself.  2 
Naturally, our study also has limitations. Having used administrative data, we defined 3 
AIS using ICD-10 codes and thus lacked more detailed information regarding stroke severity, 4 
or classification. Nevertheless, all analyses were adjusted for a wide range of confounders 5 
including some important predictors of severe or cardioembolic stroke, such as atrial 6 
fibrillation and heart failure39,40, which may have partly accounted for stroke severity or 7 
classification. Furthermore, we also lacked more information regarding cancer staging except 8 
for metastases. We were thus unable to further stratify our analyses by cancer stage. Our 9 
database also did not capture treatments such as antithrombotic therapy, which may 10 
contribute to the differences in outcomes. Finally, our study only assessed in-hospital 11 
outcomes and further research including is also required to characterise the long-term stroke 12 
outcomes after hospital discharge associated with co-morbid cancer as well as their 13 
interaction with revascularisation strategies.  14 
In conclusion, in this study of a sample representative of 1.1 million AIS admissions 15 
across the United States between 2015-2017, we reported that patients with cancer represent 16 
one in thirty acute stroke admissions in the United States and are associated with an increased 17 
risk of mortality. We also report that even after adjustment for differences in comorbidity, 18 
patients with cancer are less likely to be offered revascularisation therapies. These disparities 19 
in care may contribute to some of the observed adverse outcomes associated with a cancer 20 
diagnosis. Nevertheless, IVT offset the non-metastatic cancer-associated excess odds of 21 
mortality, while ET offset both the non-metastatic and metastatic cancer-associated excess 22 
odds of mortality. Both non-metastatic and metastatic cancers were associated with increased 23 
odds of prolonged hospitalisation and decreased odds of routine discharge. IVT and ET are 24 
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useful strategies to improve in-hospital outcomes in this population and should be offered 1 
routinely in cancer patients unless otherwise contraindicated.  2 
 3 
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TABLES 
Table 1. Patient characteristics on admission, stratified by either co-existent non-metastatic or metastatic cancer. Further descriptive statistics 
are detailed in Supplemental Table III (please see https://www.ahajournals.org/journal/str). 
 
 All No Active Cancer Non-metastatic Cancer Metastatic Cancer P value 
N 1,106,045 1,067,190 20,895 17,960 
 
Age, median (IQR) 72.00 (61.00-82.00) 71.00 (60.00-82.00) 75.00 (67.00-83.00) 70.00 (62.00-78.00) <0.001 
Length-of-stay, 
median (IQR) 
3.00 (2.00-6.00) 3.00 (2.00-6.00) 4.00 (2.00-7.00) 4.00 (2.00-7.00) <0.001 
Sex 
Female, N (%) 
557595 (50.41) 538635 (50.47) 9795 (46.88) 9165 (51.03) <0.001 
Ethnicity     <0.001 
White 735330 (66.48) 707550 (66.30) 15005 (71.81) 12775 (71.13)  
Black 183090 (16.55) 177790 (16.66) 2880 (13.78) 2420 (13.47)  
Hispanic 84950 (7.68) 82700 (7.75) 1240 (5.93) 1010 (5.62)  
Asian or Pacific Islander 31635 (2.86) 30500 (2.86) 530 (2.54) 605 (3.37)  
Native American 4700 (0.42) 4570 (0.43) 60 (0.29) 70 (0.39)  
Other 27460 (2.48) 26535 (2.49) 410 (1.96) 515 (2.87)  
ELIXHAUSER CO-
MORBIDITIES, N (%)      
Congestive Heart Failure 172170 (15.57) 166950 (15.64) 3225 (15.43) 1995 (11.11) <0.001 
Valvular Disease 110540 (9.99) 106640 (9.99) 2300 (11.01) 1600 (8.91) 0.008 
Pulmonary Circulation 
Disease 
8460 (0.76) 6710 (0.63) 555 (2.66) 1195 (6.65) <0.001 
Peripheral Vascular 
Disease 
112065 (10.13) 107955 (10.12) 2470 (11.82) 1640 (9.13) <0.001 
Paralysis 112895 (10.21) 108920 (10.21) 2260 (10.82) 1715 (9.55) 0.178 
Other Neurological 
Disorders 
6620 (0.60) 6275 (0.59) 210 (1.01) 135 (0.75) 0.001 
A
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174180 (15.75) 165690 (15.53) 4795 (22.95) 3695 (20.57) <0.001 
Diabetes (without 
chronic complications) 
210220 (19.01) 203765 (19.09) 3520 (16.85) 2935 (16.34) <0.001 
Diabetes (with chronic 
complications) 
214400 (19.38) 209135 (19.60) 3095 (14.81) 2170 (12.08) <0.001 
Hypothyroidism 159160 (14.39) 153810 (14.41) 2950 (14.12) 2400 (13.36) 0.193 
Renal Failure 181950 (16.45) 175960 (16.49) 3670 (17.56) 2320 (12.92) <0.001 
Liver Disease 18310 (1.66) 17275 (1.62) 550 (2.63) 485 (2.70) <0.001 
Peptic Ulcer Disease 7695 (0.70) 7400 (0.69) 175 (0.84) 120 (0.67) 0.527 
Acquired Immune 
Deficiency Syndrome 
2395 (0.22) 2280 (0.21) 100 (0.48) 15 (0.08) <0.001 
Lymphoma 5315 (0.48) 4915 (0.46) 220 (1.05) 180 (1.00) <0.001 
Rheumatoid Arthritis / 
Collagen Vascular 
Disease 
30150 (2.73) 29240 (2.74) 520 (2.49) 390 (2.17) 0.075 
Coagulopathy 41405 (3.74) 37105 (3.48) 1560 (7.47) 2740 (15.26) <0.001 
Obesity 145465 (13.15) 142575 (13.36) 1775 (8.49) 1115 (6.21) <0.001 
Weight loss 44030 (3.98) 39685 (3.72) 1795 (8.59) 2550 (14.20) <0.001 
Fluid and electrolyte 
disorders 
246680 (22.30) 235750 (22.09) 5200 (24.89) 5730 (31.90) <0.001 
Anaemia (chronic blood 
loss) 
4025 (0.36) 3590 (0.34) 240 (1.15) 195 (1.09) <0.001 
Anaemia (deficiency) 133005 (12.03) 123720 (11.59) 4375 (20.94) 4910 (27.34) <0.001 
Alcohol abuse 49375 (4.46) 48080 (4.51) 800 (3.83) 495 (2.76) <0.001 
Drug abuse 28985 (2.62) 28365 (2.66) 355 (1.70) 265 (1.48) <0.001 
Psychoses 26255 (2.37) 25490 (2.39) 440 (2.11) 325 (1.81) 0.041 
Depression  124635 (11.27) 120280 (11.27) 2330 (11.15) 2025 (11.28) 0.971 
Hypertension 946140 (85.54) 916430 (85.87) 16975 (81.24) 12735 (70.91) <0.001 
PROCEDURES, N (%)      
A
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Thrombectomy 34420 (3.11) 33090 (3.10) 670 (3.21) 660 (3.67) 0.139 
Thrombolysis 103600 (9.37) 101035 (9.47) 1730 (8.28) 835 (4.65) <0.001 
OUTCOMES, N (%)      
In-hospital mortality 43545 (3.94) 40545 (3.80) 1230 (5.89) 1770 (9.86) <0.001 
Length-of-stay >4 days 380605 (34.41) 363430 (34.05) 8680 (41.54) 8495 (47.30) <0.001 
Routine Discharge 394105 (35.99) 384490 (36.39) 5600 (26.94) 4015 (22.52) <0.001 
A
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Figure 2. Distribution of each primary cancer type amongst the included sample of acute 
ischaemic stroke patients, representative of 1,106,045 patients. 
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Figure 3. Results of multivariable logistic regressions assessing the association between co-
morbid cancer (non-metastatic and metastatic) and acute ischaemic stroke in-hospital 
outcomes as well as the interaction with revascularisation therapies. 
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Figure 4. Results of multivariable logistic regressions assessing the association between the 5 
most commonly occurring cancer types in the included cohort and acute ischaemic stroke in-
hospital mortality as well as the interaction with revascularisation therapies. 
 
OR – odds ratio; CI – confidence interval; IVT – intravenous thrombolysis; ET – 
endovascular thrombectomy 
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